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Background: Although liver resection (LR) for colorectal cancer (CRC) hepatic metastasis is the best strategy to
improve patient outcomes, there are considerable concerns regarding the recurrence of CRC after LR. In this study,
we investigated the prognostic indicators associated with CRC recurrence after LR for hepatic metastasis.
Methods: This is a retrospective review of patients who underwent curative LR for CRC hepatic metastasis between
January 2008 and December 2012. The clinicopathological features and outcome parameters affecting prognosis
were analyzed.
Results: A total of 332 LRs with curative intent were performed in 278 patients, of whom 168 (60.4%) experienced
CRC recurrence after the first LR, and 206 of the 332 LRs (62.0%) developed CRC recurrence. A preoperative serum
carcinoembryonic antigen level greater than 100 ng/mL and four or more metastatic tumor nodules were
independent prognostic factors for CRC recurrence after LR. The disease-free survival rate after LR was significantly
associated with the number of metastatic nodules. The patients who underwent surgical resection for recurrent
CRC had favorable outcomes, with a five-year overall survival rate of 65.2%.
Conclusion: The number of metastatic tumors significantly affects the outcomes of patients who undergo LR for
CRC hepatic metastasis, indicating that a novel therapeutic strategy for patients at high risk may be required.
However, favorable long-term outcomes are achievable through aggressive treatment with surgical resection of the
recurrent CRC.
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The liver is the most common site of distant spread of
primary colorectal cancer (CRC), and over 50% of patients
will develop hepatic metastasis during the course of their
disease [1,2]. Liver resection (LR) is believed to provide
the only chance of curative treatment, and has largely
improved the long-term outcomes of these patients if
the metastatic CRC is confined to the liver [2-4]. With the
introduction of multidisciplinary treatment and the
advancement of surgical management and chemotherapeutic* Correspondence: chankunming@adm.cgmh.org.tw
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unless otherwise stated.agents, the five-year survival rate following LR with
curative intent for CRC hepatic metastasis has been
reported to be up to 60% in recently published studies
[5-7]. Nevertheless, despite the excellent results of surgical
resection for metastatic CRC, it is estimated that more
than half of the patients will still develop recurrence
within two years [8,9].
CRC is a common gastrointestinal malignancy world-
wide, and has recently been reported to be the most
common cancer in East Asian countries. LR is increas-
ingly being used as the standard practice for CRC
hepatic metastasis as well. Although numerous previ-
ous studies have reported prognostic factors capable of
predicting the outcomes for CRC patients undergoing
LR for hepatic metastasis [5,10-12], predictors for CRCtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological characteristics of the patients






Age (years), median (range) 60.4 (29.1 to 88.0) 60.9 (29.1 to 88.0)
Gender
Male 186 (66.9%) 225 (67.8%)
Female 92 (33.1%) 107 (32.2%)
Primary tumor location
Colon 178 (64.0%) 206 (62.0%)
Rectum 100 (36.0%) 126 (38.0%)
Type of initial hepatic metastasis
Synchronous 153 (55.0%) 153 (46.1%)
Metachronous 125 (45.0%) 179 (53.9%)
CRC recurrence after liver
resection
Yes 168 (60.4%) 206 (62.0%)
No 110 (39.6%) 126 (38.0%)
Surgical resection of CRC
recurrence
61 (36.3%)* 74 (35.9%)*
Final patient status
Alive and CRC free 128 (46.0%) —
Alive with recurrent CRC 62 (22.3%) —
Died of CRC 79 (28.4%) —
Died of other causes 6 (2.2%) —
Surgical mortality 3 (1.1%) 3 (0.9%)
CRC, colorectal cancer; * represents the percentage among CRC recurrence.
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Moreover, despite a growing experience and literature,
it is still an issue of great concern. In the current study,
we retrospectively reviewed our experience with LR for
patients with hepatic metastasis from CRC with the
aim of providing additional information in terms of the
factors associated with the prognosis of the patients




This study included patients with CRC hepatic metas-
tasis who underwent LR with curative intent between
January 2008 and December 2012 at Chang Gung
Memorial Hospital Linkou Medical Center (Linkou,
Taiwan). A retrospective review of all medical records
was performed with approval of the Institutional Re-
view Board of Chang Gung Memorial Hospital. Data
from the medical records including clinical charac-
teristics, surgical management and outcomes were
analyzed.
Liver resection for hepatic metastasis
The clinical status of CRC and hepatic metastasis was
thoroughly evaluated using appropriate imaging studies,
including computed tomography (CT) scans of the ab-
dominal and pelvic areas, and/or chest CT for all patients
prior to surgery. Positron emission tomography (PET) or
PET/CT was not routinely performed, but was occasion-
ally performed for the patients who had equivocal conven-
tional imaging study results to confirm occult metastasis if
indicated. The treatment for CRC hepatic metastasis was
decided by consensus of the members of the multidiscip-
linary committee, which was comprised of liver surgeons,
proctologists, oncologists, radiologists and interven-
tional radiologists. Treatment options mainly depended
on the tumor’s characteristics and the patient’s physical
condition, and liver resection was always the preferred
treatment for patients with resectable hepatic metasta-
sis. Resectability of hepatic metastasis with a curative
intent required complete resection of all hepatic meta-
static lesions, and preservation of a sufficient volume of
liver with adequate vascular inflow and outflow. The
extent of LR was defined on the basis of Couinaud’s
classification. The patients with imaging evidence of
concurrent unresectable extrahepatic metastasis were
considered ineligible for LR.
Follow-up after liver resection
After LR, postoperative adjuvant chemotherapy was
recommended for all patients, unless the patient’s physical
status was unsuitable for chemotherapy or they were
unwilling to receive chemotherapy. The chemotherapeuticregimens mainly depended on the aggressiveness of the
tumor characteristics, the patient’s physical condition,
availability of the chemotherapeutic regimens, and
affordability of the chemotherapy drugs. The chemo-
therapeutic options were mostly fluorouracil plus
leucovorin and a combination of options, including
oxaliplatin, irinotecan, bevacizumab and cetuximab.
Additionally, all patients were regularly followed up
and monitored for CRC recurrence by measuring
serum carcinoembryonic antigen (CEA) levels and liver
ultrasonography one month after LR and every three
months thereafter. CT and/or magnetic resonance
imaging (MRI) was performed at yearly intervals or
whenever CRC recurrence was suspected. Disease
recurrence was determined by a tissue sample from
either a biopsy or surgical resection confirming CRC,
and/or by serial imaging examinations. All patients
were followed up until death or the end of the study
period. The strategy for the treatment of recurrent
CRC after LR was the same as that for the initial man-
agement of CRC, and depended on the consensus of
the multidisciplinary committee.
Table 2 The clinicopathological factors affecting CRC recurrence of all liver resections for hepatic metastasis
Factors Univariate analysis Multivariate analysis
n Medium RFS (m) HR, (95% CI) P-value HR, (95% CI) P-alue
Age (years)
<55 108 12.9 1.16, (0.86 to 1.55) 0.327 — —
≥55 224 14.7 1
Gender
Male 225 15.1 1 0.608 — —
Female 107 11.2 1.08, (0.80 to 1.45)
Primary tumor
Colon 206 15.1 1 0.232 — —
Rectum 126 12.0 1.11, (0.89 to 1.57)
Serum CEA (ng/mL)
<100 294 15.1 1 <0.0001 1 0.001
≥100 38 6.3 3.15, (1.83 to 5.44) 2.06, (1.36 to 3.11)
Metastatic type
Synchronous 153 14.8 1 0.757 1 0.744
Metachronous 179 13.1 0.95, (0.72 to 1.26) 1.05, (0.79 to 1.40)
Number of tumors
<4 nodules 285 15.4 1 0.001 1 0.041
≥4 nodules 47 8.3 2.22, (1.40 to 3.51) 1.53, (1.02 to 2.29)
Maximum tumor size (cm)
<5 267 13.6 1.39, (0.99 to 1.95) 0.058 1.40, (0.95 to 2.06) 0.088
≥5 65 21.7 1 1
Distribution of metastasis
Unilobar 239 15.9 1 0.025 1 0.399
Bilobar 93 9.7 1.43, (1.40 to 1.98) 1.16, (0.82 to 1.63)
Extent of liver resection
<3 segments 262 14.6 1 0.751 — —
≥3 segments 70 13.1 0.95, (0.68 to 1.32)
Resection margin (mm)
<0.5 142 11.5 1.42, (1.08 to 1.88) 0.012 1.28, (0.95 to 1.71) 0.103
≥0.5 190 16.8 1 1
Histologic grade
Low-moderate grade 321 14.4 1 0.112 1 0.237
High grade 11 6.9 1.92, (0.86 to 4.28) 1.50, (0.77 to 2.94)
Postoperative chemotherapy
Fluorouracil 57 12.5 1.28, (0.85 to 1.93) 0.326 1.19, (0.80 to 1.76) 0.712
Oxaliplatin base 140 16.8 1 1
Irinotecan base 103 12.8 1.34, (0.85 to 1.93) 1.19, (0.85 to 1.65)
No 32 13.6 1.00, (0.60 to 1.67) 1.15, (0.68 to 1.95)
Associated with bevacizumab
Yes 46 17.0 1 0.496 — —
No 286 13.5 1.15, (0.77 to 1.72)
Associated with cetuximab
Yes 6 7.4 1.80, (0.52 to 6.25) 0.352 — —
No 326 14.4 1
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Table 2 The clinicopathological factors affecting CRC recurrence of all liver resections for hepatic metastasis (Continued)
Chemotherapy cycles
≥6 232 15.4 1 0.233 — —
<6 100 9.7 1.21, (0.89 to 1.65)
CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio; RFS, recurrence free survival.
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All statistical analyses were performed using SPSS
statistical software version 17.0 (SPSS, Inc., Chicago,
IL, USA) and Prism 5.0 (GraphPad Software, San
Diego, CA, USA) for Windows. The end-point out-
come measures were recurrence-free survival (RFS)
and overall survival (OS). RFS was defined as the date
of each LR to the date of detected CRC recurrence or
the date of the last follow-up if there was no CRC
recurrence. OS was defined as the date of the first LR
to the date of death or the date of the last follow-up.
Survival analysis was conducted using the Kaplan-
Meier method. Variables were analyzed by multiva-
riate analysis using a Cox regression proportional hazards
model to identify the factors influencing RFS on the
basis of each LR. An optimal cutoff value for continuous
variables was determined by receiver-operating charac-
teristic (ROC) curve analysis. All significant prognostic
factors determined by univariate analysis and important
clinical variables were then entered into multivariate
analysis. Statistical significance was set at a P-value of
less than 0.05.Table 3 CRC recurrence and surgical resection of
recurrent lesions
Recurrent features CRC recurrence† Surgical resection*
Number of patients 168 61
Location of recurrence
Single anatomic site
Abdominal wall 2 (1.0%) 2 (2.7%)
Intraabdominal mass 16 (7.8%) 4 (5.4%)
Liver 90 (43.7%) 53 (71.6%)
Lung 29 (14.1%) 12 (16.2%)
Brain 3 (1.4%) 2 (2.7%)
Bone 3 (1.4%) 0 (0%)
Multiple anatomic sites
Liver and lung 35 (17.0%) 1 (1.3%)
Systemic spreading 28 (13.6%) 0 (0%)
Total 206 recurrences 74 surgical resections
CRC, colorectal cancer; †percentages represent the ratio among
total recurrences;
*Percentages represent the ratio among total surgical resections.Results
Clinical characteristics of the patients
A total of 332 LRs with curative intent were performed
in 278 patients in this study. Of these patients, 186
(66.9%) were men and 92 (33.1%) were women, and the
median age at the time of the first LR was 60.4 years
(range, 29 to 88 years). After the first LR, the median
follow-up period for the included patients was 23.8
months (range, 2 days to 108 months). Table 1 summa-
rizes the clinical characteristics of the patients who
underwent LR for CRC hepatic metastasis. The primary
malignancy was located in the colon in 64% of the pa-
tients and 62% of the LRs. During follow-up, 168 pa-
tients (60.4%) experienced CRC recurrence after the
first LR, and 206 of the 332 LRs (62.0%) developed CRC
recurrence. Of the 168 patients with CRC recurrence,
61 (36.3%) underwent surgical resection for the CRC
recurrence, and 74 (35.9%) surgical resections were per-
formed for the 206 cases of CRC recurrence after LR.
There were three cases of surgery-related mortality, and
the mortality rates were 1.1% and 0.9% for all patients
and the LRs, respectively.Recurrence after liver resection of hepatic metastasis
Among the 332 LRs, the prognostic factors affecting
CRC recurrence after LR were further analyzed and are
summarized in Table 2. Univariate analysis identified
the following five factors: preoperative serum CEA
level, number of tumors, maximum tumor size, distri-
bution of hepatic metastasis, and distance of resection
margins. However, multivariate regression analysis of
the prognostic factors showed that a preoperative serum
CEA level ≥100 ng/mL (P = 0.0001, hazard ratio (HR) =
2.06) and four or more tumor nodules (P = 0.041, HR =
1.53) were independent prognostic factors of CRC re-
currence following LR for hepatic metastasis.
Of the 168 patients who developed CRC recurrence
after LR, 206 cases of CRC recurrence, including 143
(69.4%) at a single anatomic site and 63 (30.6%) at
multiple anatomic sites or systemic spreading, were
detected. Table 3 summarizes the location of CRC
recurrence and the surgical management; 74 surgical
resections including 54 repeat LRs were performed for
61 patients accounting for 35.9% of the LRs with CRC
recurrence and 36.3% of patients with CRC recurrence,
respectively. With regards to the LRs, 44 patients
received multiple LRs, and 2 of them underwent up to
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were alive with CRC recurrence and 128 (46.0%) were
alive without evidence of CRC at the end of the study
period (Figure 1).Survival analysis of the patients
During the follow-up period, the median time of CRC
recurrence after LR was 10.3 months, and the three- and
five-year RFS rates were 25.5% and 20.8%, respectively.
The median time of survival for all patients (n = 278)
after the first LR was 23.7 months, with three- and five-
year OS rates of 60.4% and 52.1%, respectively (Figure 2).
Of those with CRC recurrence, the median survival after
the first detection of recurrence was 14.4 months. The
survival curve of the patients who underwent surgical
resection for recurrent CRC was better than that of the
patients who did not undergo surgical resection for
recurrent CRC. The three-year survival rates after CRC
recurrence were 60.0% and 16.8% for the patients with
and without surgical resection, respectively (Figure 3A,
P <0.0001). Moreover, the five-year OS rate of the
patients who underwent surgical resection for CRC
recurrence increased to 65.2% after the first LR, whereas
the five-year OS rate of the patients who did not undergo
surgical resection for CRC recurrence was only 16.0%
(Figure 3B, P <0.0001).
With regards to the number of metastatic tumors, the
RFS of the patients was significantly associated with the
number of metastatic nodules in the liver. The results
showed that patients with a solitary metastatic tumor
had a better survival curve, and the five-year RFS rate
was 28.8%. As the number of tumor nodules increased,
the actuarial RFS showed a significant decrease. Patients
with four or more hepatic metastatic tumor nodules had
the worst outcomes, with a five-year RFS rate of less
than 10% (Figure 4, P = 0.002).Figure 1 The final status of the patients related to the number
of liver resections.Discussion and conclusion
Liver resection currently offers the best chance of sur-
vival and potential cure for patients with CRC hepatic
metastasis, and numerous reports have demonstrated
long-term survival benefits [5-7]. Along with advances
in preoperative preparation, both resectability and OS
of patients with CRC hepatic metastasis have shown
remarkable improvements [13-15]. However, similar to
patients who undergo surgical resection for primary
cancer, CRC recurrence after LR for hepatic metastasis
remains a concern worldwide. In this study, we found
that the rate of cancer recurrence was still very high,
and involved nearly 60% of the patients after LR for
hepatic metastasis from CRC. However, the results also
demonstrated that aggressive surgical resection for
recurrent CRC was beneficial.
The treatment strategies regarding hepatic metastasis
from CRC have changed along with advancements in
systemic therapy in the last decade. Recent evidence has
demonstrated that systemic chemotherapy contributes
to improvements in OS in patients with hepatic metasta-
sis from CRC [16-18], and that it is effective even as
neoadjuvant therapy [19]. Although numerous factors
probably affect prolonging patient survival, the use of
chemotherapy clearly plays a key role. However, the
importance of postoperative adjuvant chemotherapy was
not found in this study. A possible explanation could be
that the adjuvant chemotherapy regimens in our patients
were not identical, and comparisons of patients grouped
by differing chemotherapeutic regimens may have been
limited by the small number of patients in each group.
Unfortunately, no consensus currently exists regarding
which therapeutic protocol is the best for the prevention
of CRC recurrence after LR, and further studies to clarify
the effect of specific postoperative adjuvant chemotherapy
regimens on RFS are required.Figure 2 Kaplan-Meier cumulative survival curves of the
patients who underwent liver resection (LR) for colorectal
cancer (CRC) hepatic metastasis by recurrence-free survival
(RFS) and overall survival (OS).
Figure 3 Kaplan-Meier survival curves of the patients with
colorectal cancer (CRC) recurrence after liver resection. A. The
patients who underwent surgical resection for CRC recurrence had a
significantly better survival curve than those who did not undergo
surgical resection for CRC recurrence. The three-year survival rates after
CRC recurrence were 60.0% and 16.8% for the patients who did and
did not undergo surgical resection of recurrent CRC, respectively
(P <0.0001). B. The cumulative overall survival rates calculated from the
first liver resection showed significant survival benefits for the patients
who underwent surgical resection for CRC recurrence. The five-year
overall survival rates were 65.2% and 16.0%, respectively (P <0.0001).
Figure 4 The recurrence-free survival (RFS) curves of the
patients after liver resection in terms of the number of hepatic
metastatic tumors. The patients with solitary metastatic tumors
had the best RFS curve, and the RFS curves became worse as the
number of tumor nodules increased (P = 0.002).
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prognostic factors affect the outcomes of patients who
undergo LR for hepatic metastasis from CRC, and
similar factors were also noted in this study. The pres-
ence of multiple hepatic metastatic tumors seems to be
a very important risk factor for CRC recurrence after
LR [11,15]. Patients with multiple hepatic metastases,
and specifically more than four tumor nodules, have
been reported to be associated with a poor prognosis,
and many surgeons are therefore reluctant to perform
LR for these patients. Nevertheless, several studies
have indicated that long-term survival is achievable
after LR for multiple CRC hepatic metastases [20-22].
Furthermore, the safety of hepatic resection and moreeffective adjuvant chemotherapy also support the con-
cept of an aggressive surgical approach for patients
with multiple CRC hepatic metastases. Due to the lack
of other potentially curative alternatives, the presence
of multiple hepatic metastases should not be consid-
ered as a contraindication for LR.
Surgical resection of metastatic lesions with cura-
tive intent is currently the treatment of choice for
several malignancies [23-25], including for patients
with recurrence after LR for CRC hepatic metastasis
[26,27]. Our results also showed that surgical resec-
tion of isolated recurrent lesions was beneficial in
selected patients who underwent LR for CRC hepatic
metastasis. Although the prognosis of patients who
are suitable for surgical resection may be better than
for patients who are ineligible for surgical resection,
an aggressive attitude in terms of surgical resection
still seems to be beneficial. As shown in the current
study, many of the patients were alive without CRC
recurrence after multiple LRs. Moreover, sequential
resection with curative intent for multiple metastases
in various anatomic sites may also offer favorable sur-
vival outcomes.
Taken together, despite distant metastasis and the clin-
ical indication as a terminal-stage cancer, CRC is one of
the few malignancies for which patients with metastasis
confined to a single organ may obtain long-term survival
through multidisciplinary treatment. However, CRC re-
currence remains a problem that affects more than half
of the patients who undergo LR for hepatic metastasis.
Due to the beneficial results of surgical resection for re-
current lesions, it is essential to regularly and frequently
follow-up patients in the first few years after LR to
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sectable stage. In addition, to achieve better long-term
outcomes for patients with CRC and effectively treat
hepatic metastasis, the development of a treatment
protocol that involves surgery and chemotherapeutic
regimens is indicated.
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